Work

A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5089

Authors: Mototsugu Oya, Satoshi Tamada, Katsunori Tatsugami, Noboru Nakaigawa, Takahiro Osawa, Hiro-Omi Kanayama, Chihiro Kondoh, Naoto Sassa, Kazuo Nishimura, Masahiro Nozawa, Naoya Masumori, Yasuhide Miyoshi, Akiko Kimura, Shingo Kuroda, Robert J. Motzer, Toni K. Choueiri, Yoshihiko Tomita

Institutions: Keio University, Osaka City University, Kyushu University, Yokohama City University, Hokkaido University, Tokushima University, Toranomon Hospital, Nagoya University, Osaka International Cancer Institute, Kindai University, Sapporo Medical University, Yokohama City University Medical Center, Takeda (Japan), Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Niigata University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3031556809

Cites:

Cited by: 6

Related to: 10